DOJ Aims to Sidestep Generic-Drug Label Suit Review, GSK Says

The Biden administration is trying to promote generic-drug labeling despite where the facts and previous court decisions point, GlaxoSmithKline Plc told Supreme Court justices Tuesday in a dispute with Teva Pharmaceuticals USA Inc.

The government seeks to “relieve Teva of the consequences of its actions” after releasing a copycat version of GSK’s heart drug Coreg and being found liable for infringement, GSK said in a supplemental brief filed Tuesday. Instead of advocating for Supreme Court review, the government should let a remand of the case—which will examine one of Teva’s yet-unaddressed defenses—play out in a Delaware bench trial, according to ...